Clinical practice of 177Lu-PSMA-RLT in the treatment of prostate cancer
10.3760/cma.j.cn321828-20191024-00233
- VernacularTitle:177Lu-PSMA-RLT治疗前列腺癌临床实践技术
- Author:
Lei LEI
1
;
Xuedan WANG
;
Zhijun ZHOU
;
Nan LIU
;
Li ZHANG
;
Yue CHEN
;
Wei ZHANG
Author Information
1. 西南医科大学附属医院核医学科、核医学与分子影像四川省重点实验室，泸州 646000
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2020;40(10):621-624
- CountryChina
- Language:Chinese
-
Abstract:
Prostate cancer is one of the malignant tumors with high incidence. Although most patients with prostate cancer respond well to standard treatment, they often have a poor prognosis once they develop hormone resistance. Radionuclide targeted therapy is an important method to treat malignant tumors after surgery and chemo-radiotherapy. New radioligand therapy (RLT), represented by 177Lu-prostate specific membrane antigen (PSMA)-RLT, effectively solves the problem of poor efficacy in advanced hormone-resistant prostate cancer, and has been widely recognized in the world. In this paper, the clinical practice of 177Lu-PSMA-RLT in the treatment of prostate cancer and its common adverse reactions are described in order to better understand and master its methods and lay the foundation for better clinical application and follow-up research.
